News Novartis drug flunks phase 3 test in giant cell arteritis Novartis hopes of bringing Cosentyx to patients with giant cell arteritis seem to be over after the drug missed all the endpoints in a phase 3 trial.
News Rinvoq cleared for giant cell arteritis in EU, ahead of US AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis.
News AbbVie closes on Rinvoq approval in inflamed artery disease AbbVie's Rinvoq is poised to become the first oral targeted treatment for giant cell arteritis in the EU after being backed by the CHMP.
News Roche to file Actemra in inflamed artery disease Drug successful in late stage trial for giant cell arteritis
News NHS trust rolls out digital health tool for kidney disease An NHS trust in England is starting a pilot study of a digital health platform that promises to improve the care of people with kidney disease.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face